Free Trial

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Cyclerion Therapeutics logo
$3.30 +0.20 (+6.45%)
Closing price 07/2/2025 03:57 PM Eastern
Extended Trading
$3.26 -0.03 (-1.06%)
As of 07:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cyclerion Therapeutics Stock (NASDAQ:CYCN)

Key Stats

Today's Range
$3.11
$3.50
50-Day Range
$2.75
$3.70
52-Week Range
$1.27
$9.47
Volume
141,823 shs
Average Volume
1.27 million shs
Market Capitalization
$10.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyclerion Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
23rd Percentile Overall Score

CYCN MarketRank™: 

Cyclerion Therapeutics scored higher than 23% of companies evaluated by MarketBeat, and ranked 838th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Cyclerion Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclerion Therapeutics is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclerion Therapeutics is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cyclerion Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cyclerion Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.66% of the float of Cyclerion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclerion Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclerion Therapeutics has recently increased by 25.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cyclerion Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cyclerion Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.66% of the float of Cyclerion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclerion Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclerion Therapeutics has recently increased by 25.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cyclerion Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cyclerion Therapeutics' insider trading history.
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Stock News Headlines

Cyclerion Therapeutics files $25M mixed securities shelf
3 US Penny Stocks With Market Caps Over $10M To Consider
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
Cyclerion Therapeutics announces update on next stage of growth
See More Headlines

CYCN Stock Analysis - Frequently Asked Questions

Cyclerion Therapeutics' stock was trading at $3.22 at the beginning of 2025. Since then, CYCN shares have increased by 2.5% and is now trading at $3.30.
View the best growth stocks for 2025 here
.

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its earnings results on Tuesday, March, 4th. The company reported $0.22 earnings per share (EPS) for the quarter. The firm had revenue of $1.81 million for the quarter.

Shares of Cyclerion Therapeutics reverse split on Tuesday, May 16th 2023.The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
3/04/2025
Today
7/03/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCN
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.06 million
Pretax Margin
-141.47%

Debt

Sales & Book Value

Annual Sales
$2 million
Price / Cash Flow
N/A
Book Value
$3.27 per share
Price / Book
1.01

Miscellaneous

Free Float
2,109,000
Market Cap
$10.59 million
Optionable
No Data
Beta
1.55
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CYCN) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners